Clinical Trial Update: Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating intratumoral Vusolimogene Oderparepvec (VO) in combination with Pembrolizumab for angiosarcoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vusolimogene Oderparepvec (Vusolimogene Oderparepvec)

Snippet

Sponsor: Varun Monga, MBBS | Conditions: Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Status: RECRUITING